



(43) International Publication Date  
4 April 2013 (04.04.2013)

(10) International Publication Number  
**WO 2013/049161 A1**

- (51) **International Patent Classification:**  
*C08G 63/06* (2006.01) *C08G 63/08* (2006.01)
- (21) **International Application Number:**  
PCT/US2012/057277
- (22) **International Filing Date:**  
26 September 2012 (26.09.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/539,695 27 September 2011 (27.09.2011) US
- (71) **Applicant:** TEPHA, INC. [US/US]; 99 Hayden Avenue, Suite 360, Lexington, MA 02421 (US).
- (72) **Inventors:** GUO, Kai; 205 Kent Street #B1, Brookline, MA 02446 (US). MARTIN, David, P.; 33 Hemlock Street, Arlington, MA 02474 (US).
- (74) **Agents:** MONHEIT, Rivka, D. et al.; Pabst Patent Group LLP, 1545 Peachtree Street, N. E., Suite 320, Atlanta, GA 30309 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title:** CONTROLLED HYDROLYSIS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS

(57) **Abstract:** Methods for making P4HB polymers and copolymers thereof that are useful for preparing controlled release systems, medical devices and as intermediates in chemical synthesis, have been developed. These methods avoid the use of organic solvents, and basic conditions that can cause transesterification reactions with polymer terminal end groups or elimination reactions. A preferred embodiment is a method for producing polymers of P4HB with weight average molecular weight less than 250,000, and more preferably, less than 100,000, and a Pd of less than 3, which are useful in controlled release. A particularly preferred embodiment utilizes aqueous acetic acid to hydrolyze pellets of P4HB polymers and copolymers while in suspension.



WO 2013/049161 A1


## CONTROLLED HYDROLYSIS OF POLY-4-HYDROXYBUTYRATE AND COPOLYMERS

### Field of the Invention

The present invention generally relates to methods for controlling the hydrolysis of poly-4-hydroxybutyrate and copolymers thereof, and to compositions of poly-4-hydroxybutyrate and copolymers thereof with specific weight average molecular weights. The compositions can be used in implantable medical devices, controlled release applications, such as drug delivery, and certain compositions may be used for therapeutic delivery of 4-hydroxybutyrate. The compositions may also be used in blends, and as intermediates in synthesis.

### Background of the Invention

Poly-4-hydroxybutyrate (P4HB) and copolymers thereof can be produced using transgenic fermentation methods, see, for example, U.S. Patent No. 6,548,569 to Williams *et al.*, and are produced commercially, for example, by Tephra, Inc. (Lexington, MA). Poly-4-hydroxybutyrate (P4HB, TephraFLEX<sup>®</sup> biomaterial) is a strong, pliable thermoplastic polyester that, despite its biosynthetic route, has a relatively simple structure.



The polymer belongs to a larger class of materials called polyhydroxyalkanoates (PHAs) that are produced by numerous microorganisms (see, for example, Steinbüchel A., et al. Diversity of Bacterial Polyhydroxyalkanoic Acids, *FEMS Microbial. Lett.* 128:219-228 (1995)). In nature these polyesters are produced as storage granules inside cells, and serve to regulate energy metabolism. They are also of commercial interest because of their thermoplastic properties, and relative ease of production. Several biosynthetic routes are currently known to produce P4HB as shown in Figure 1.

Chemical synthesis of P4HB has been attempted, but it has been impossible to produce the polymer with a sufficiently high molecular weight that is necessary for most applications (see Hori, Y., et al., *Polymer* 36:4703-4705 (1995); Houk, K.N., et al., *J. Org. Chem.*, 2008, 73 (7), 2674-2678; and  
5 Moore, T., et al., *Biomaterials* 26:3771-3782 (2005)). In fact, it has been calculated to be thermodynamically impossible to chemically synthesize a high molecular weight homopolymer under normal conditions (Moore, T., et al., *Biomaterials* 26:3771-3782 (2005)).

U.S. Patent Nos 6,245,537, 6,623,748 and 7,244,442 describe  
10 methods of making PHAs with little to no endotoxin, which is suitable for medical applications. U.S. Patent Nos. 6,548,569, 6,838,493, 6,867,247, 7,268,205, and 7,179,883 describe use of PHAs to make medical devices. Copolymers of P4HB include 4-hydroxybutyrate copolymerized with 3-hydroxybutyrate or glycolic acid (U.S. patent application No. 20030211131  
15 by Martin and Skraly, U.S. Patent No. 6,316,262 to Huisman *et al.*, and U.S. Patent No. 6,323,010 to Skraly *et al.*). Methods to control molecular weight of PHA polymers by biosynthetic methods have been disclosed by U.S. Patent No. 5,811,272 to Snell *et al.*

PHAs with controlled degradation and degradation *in vivo* of less  
20 than one year are disclosed by U.S. Patent No. 6,548,569, 6,610,764, 6,828,357, 6,867,248, and 6,878,758 to Williams *et al.* and WO 99/32536 to Martin *et al.* Applications of P4HB have been reviewed in Williams, S.F., et al., *Polyesters, III*, 4:91-127 (2002), and by Martin, D. *et al.* Medical Applications of Poly-4-hydroxybutyrate: A Strong Flexible Absorbable  
25 Biomaterial, *Biochem. Eng. J.* 16:97-105 (2003). Medical devices and applications of P4HB have also been disclosed by WO 00/56376 to Williams *et al.* Several patents including U.S. Patent Nos. 6,555,123, 6,585,994, and 7,025,980 describe the use of PHAs in tissue repair and engineering.

In controlled release there currently exists a need for P4HB and  
30 copolymers thereof with narrowly defined weight average molecular weight ranges. By controlling these ranges, compositions can be developed that allow the controlled release of a wide range of bioactive agents. Particularly

desired compositions include polymers with weight average molecular weights less than 250,000, and more preferably less than 100,000. Preferably, the compositions should have a polydispersity of less than 3, and more preferably less than 2.5.

5           In addition to being useful in controlled release, lower molecular weight compositions of P4HB and copolymers thereof can be useful in the preparation of other chemicals, polymers, copolymers, and for blending with other materials. For example, low molecular weight P4HB and copolymers thereof can be used in the preparation of polyurethanes or as nucleants or  
10   fillers in blends.

US Patent No. 6,623,730 to Williams and Martin discloses the use of oligomers of P4HB as prodrugs to modulate endogenous levels of 4-hydroxybutyrate, and methods to prepare these oligomers by hydrolysis of P4HB. The method disclosed uses aliquots of sodium methoxide to  
15   hydrolyze P4HB dissolved in a solvent (anhydrous THF) to provide the oligomers of P4HB of the desired molecular weight. Starting with a polymer of molecular weight 430,000 g/mol, sodium methoxide is used to produce P4HB molecular weights of 320,000, 82,000 and 25,000. The disadvantages of this procedure are as follows: (i) the use of methoxide can result in  
20   terminal esterification of the polyester chains (producing methyl esters); (ii) the relatively low solubility of P4HB in THF (and other solvents) requires large volumes of solvent to dissolve the polymer which is difficult to handle, expensive, and costly to remove; and (iii) basic conditions could potentially lead to elimination reactions in the polymer causing unwanted side reactions.

25           It is an object of the present invention to provide methods to produce P4HB and copolymers thereof by hydrolysis of high molecular weight P4HB and copolymers without the use of solvents.

It is a further object of the present invention to provide methods to produce P4HB and copolymers thereof by hydrolysis of high molecular  
30   weight P4HB and copolymers without the use of basic conditions that can esterify polymer terminal end groups or cause basic elimination in the polymer chains.

It is another object of the present invention to provide methods for hydrolysis of P4HB and copolymers thereof that maintain the polymers in solid state during hydrolysis resulting in easy isolation of the hydrolyzed products.

5 It is still another object of the present invention to provide compositions of P4HB and copolymers thereof that can be used in medical applications, for example, in implantable medical devices and or for the controlled release of bioactive substances, including the controlled release of 4-hydroxybutyrate.

## 10 **Summary of the Invention**

Methods for making P4HB polymers and copolymers thereof that are useful for preparing controlled release systems, and as intermediates in chemical synthesis, have been developed. These methods avoid the use of organic solvents, and basic conditions that can cause transesterification reactions with polymer terminal end groups or elimination reactions. A preferred embodiment is a method for producing polymers of P4HB with weight average molecular weight less than 250,000, and more preferably, less than 100,000, which are useful in controlled release. A particularly preferred embodiment utilizes aqueous acetic acid to hydrolyze pellets of P4HB polymers and copolymers while in suspension.

## **Brief Description of the Drawings**

Figure 1 is a diagram of pathways leading to the biosynthesis of poly-4-hydroxybutyrate.

Figure 2 is a <sup>1</sup>H NMR spectrum of hydrolysis product of P4HB in acetic acid for 27.5 hours.

## **Detailed Description of the Invention**

### **Definitions**

“Poly-4-hydroxybutyrate” as generally used herein means a homopolymer comprising 4-hydroxybutyrate units. It may be referred to herein as P4HB or Tephaflex<sup>®</sup> biomaterial (manufactured by Tephaflex, Inc., Lexington, MA).

“Copolymers of poly-4-hydroxybutyrate” as generally used herein means any polymer comprising 4-hydroxybutyrate with one or more different hydroxy acid units.

5 “Controlled release” or “modified release, as used herein, refers to a release profile in which the drug release characteristics of time course and/or location are chosen to accomplish therapeutic or convenience objectives not offered by conventional dosage forms such as solutions, suspensions, or promptly dissolving dosage forms. Delayed release, extended release, and pulsatile release and their combinations are examples of modified release.

10 “Bioactive agent” is used herein to refer to therapeutic, prophylactic, and/or diagnostic agents. It includes without limitation physiologically or pharmacologically active substances that act locally or systemically in the body. A biologically active agent is a substance used for, for example, the treatment, prevention, diagnosis, cure, or mitigation of disease or disorder, a  
15 substance which affects the structure or function of the body, or pro-drugs, which become biologically active or more active after they have been placed in a predetermined physiological environment. Bioactive agents include biologically, physiologically, or pharmacologically active substances that act locally or systemically in the human or animal body. Examples can include,  
20 but are not limited to, small-molecule drugs, peptides, proteins, antibodies, sugars, polysaccharides, nucleotides, oligonucleotides, aptamers, siRNA, nucleic acids, and combinations thereof. “Bioactive agent” includes a single such agent and is also intended to include a plurality

“Blend” as generally used herein means a physical combination of  
25 different polymers, as opposed to a copolymer comprised of two or more different monomers.

“Molecular weight” as used herein, unless otherwise specified, refers to the weight average molecular weight ( $M_w$ ), not the number average molecular weight ( $M_n$ ), and is measured by gel permeation chromatography  
30 (GPC) relative to polystyrene.

“Absorbable” as generally used herein means the material is broken down in the body and eventually eliminated from the body within 5 years.

“Biocompatible” as generally used herein means the biological response to the material or device being appropriate for the device’s intended application *in vivo*. Any metabolites of these materials should also be biocompatible.

5     **I.       Composition**

Methods have been developed to produce low molecular weight (Mw) compositions of P4HB and copolymers thereof in high yield. These methods may be used to prepare P4HB and copolymers thereof with weight average molecular weights (Mw) ranging from 1 to 250 kDa, and more  
10   preferably with Mw ranging from 5 to 100 kDa. The methods also yield P4HB and copolymers with narrow polydispersity (PDI), less than 3.0 and preferably a PDI of less than 2.5. The P4HB and copolymers thereof are prepared by hydrolysis with aqueous acids, and preferably with acetic acid. A major advantage of the method is that pellets of the polymers may be  
15   suspended in acid, and hydrolyzed while in suspension to yield polymers of predictable weight average molecular weight and narrow polydispersity. In addition, purification is straightforward, side reactions are essentially absent, and yields are very high.

**A.       Polymers**

20       The processes described herein can typically be used with poly-4-hydroxybutyrate (P4HB) or a copolymer thereof. Copolymers include P4HB with another hydroxyacid, such as 3-hydroxybutyrate, and P4HB with glycolic acid or lactic acid monomer. P4HB and copolymers thereof can be obtained from Tepha, Inc. of Lexington, MA.

25       In a preferred embodiment, the starting P4HB homopolymer and copolymers thereof are extruded into pellets. An extruder can be used for this purpose. The pellets are then suspended in acid for hydrolysis. This facilitates isolation of the product, and provides a high yield of lower molecular weight product.

30       **B.       Hydrolysis**

In a preferred embodiment, P4HB and copolymers thereof can be prepared with a weight average molecular weight less than 250,000, and

more preferably, less than 100,000. It has been discovered that low molecular weight ( $M_w$ ) polymers and copolymers of P4HB can be produced with unexpectedly high yields, without solvent, and in high purity with side reactions essentially absent. Notably, the hydrolysis can be controlled so that  
5 lower molecular weight ( $M_w$ ) polymers and copolymers can be predictably produced with high purity, high yield, and with narrow polydispersity.

The polymers can be hydrolyzed by suspending the polymer in an acid or an acid solution. Therefore, in one embodiment, the acid or acid solution is one in which the polymer pellet is insoluble or partially insoluble.  
10 The acid can be an organic acid or an inorganic acid. For those embodiments where the acid is an organic acid, the acid can be a monocarboxylic acid or a polycarboxylic acid, such as a di- or tricarboxylic acid. Suitable organic acids include, but are not limited to, acetic acid, halogenated acetic acid, such as mono-, di-, trihalogenated acetic acid, lactic  
15 acid, glycolic acid, propanoic acid, butanoic acid, pentanoic acid, hexanoic acid, benzoic acid, fumaric acid, maleic acid, tartaric acid, citric acid, malic acid, and pyruvic acid. Suitable inorganic acids include, but are not limited to, hydrochloric acid, sulfuric acid, hydrobromic acid, and hydroiodic acid.

A particularly preferred embodiment utilizes aqueous acetic acid to  
20 hydrolyze P4HB polymers and copolymers. More preferably, the polymers and copolymers are first extruded into pellets, and then suspended in aqueous acid. It has been discovered that the pellets will remain suspended in the acid (with shaking or stirring) during hydrolysis as the molecular weights of the polymers decrease in a predictable manner. Even though the polymers and  
25 copolymers remain suspended, and the polymer does not dissolve, the polydispersity of the lower molecular weight ( $M_w$ ) product remains narrow. Because the pellets do not dissolve in the acid, the product may be easily isolated at the end of the hydrolysis, for example, by decanting, washing with water, and drying. There is no need to evaporate acid or solvent, or use  
30 a solvent extraction process to recover the low molecular weight polymers.

Granules or other non-pelletized forms of the polymer or copolymers can be hydrolyzed with the method, however, these forms are more likely to



become sticky during hydrolysis, making isolation of the product more difficult.

In a preferred method, the polymer or copolymer pellets are suspended in aqueous acetic acid, and either stirred or shaken. The hydrolysis may be performed at ambient or elevated temperature. Preferably the hydrolysis is undertaken at constant temperature in the range of 37 to 50°C.

The strength of the acid may be adjusted to speed up or slow down the rate of hydrolysis of the polymers and copolymers. In a preferred method, acetic acid is used with a concentration in the range of 5M to 12M. However, lower concentrations may be used to slow down the rate of hydrolysis, and higher concentrations may be used to speed up the rate of hydrolysis.

The length of the hydrolysis reaction will be determined by the molecular weight ( $M_w$ ) desired, form of the polymer or copolymer, temperature of the reaction, type of acid, and concentration of the acid. For example, pellets of P4HB ( $M_w = 346\text{kDa}$ ) suspended in aqueous acetic acid at 37°C for 4 hours will have a  $M_w = 224\text{kDa}$  if the concentration of the acid is 10M, and  $M_w = 115\text{kDa}$  if the concentration of the acid is 12M. Under the same conditions, at 27.5 hours, the molecular weights ( $M_w$ ) of the polymer with 10M and 12M acetic acid are 85kDa and 40kDa, respectively.

### **C. Uses of Low Molecular Weight P4HB and P4HB Copolymers**

Low molecular weight polymers and copolymers of P4HB have properties that are substantially improved for many medical applications relative to higher molecular weight versions. These materials have lower melt viscosities, and higher solubilities in solvents that can make them easier to process. The lower molecular weight P4HB polymer and copolymers thereof can also provide more desirable controlled release profiles for delivery of therapeutic, prophylactic or diagnostic agents or other bioactive agent, such as a small-molecule drug, peptide, protein, antibody, sugar, polysaccharide, nucleotide, oligonucleotide, aptamer, siRNA, nucleic acid,

and combinations thereof. The lower molecular weight P4HB may also be used to make medical devices, such as, but not limited to, sutures, stents, stent grafts, stent coatings, devices for temporary wound or tissue support, devices for soft or hard tissue repair, repair patches, tissue engineering  
5 scaffolds, retention membranes, anti-adhesion membranes tissue separation membranes, hernia repair devices, device coatings, cardiovascular patches, catheter balloons, vascular closure devices, slings, biocompatible coatings, rotator cuff repair devices, meniscus repair devices, adhesion barriers, guided tissue repair/regeneration devices, articular cartilage repair devices, nerve  
10 guides, tendon repair devices, intracardiac septal defect repair devices, including, but not limited to, atrial septal defect repair devices and PFO (patent foramen ovale) closure devices, left atrial appendage (LAA) closure devices, pericardial patches, bulking and filling agents, plastic surgery devices (including facial and breast cosmetic and reconstructive devices),  
15 vein valves, heart valves, bone marrow scaffolds, meniscus regeneration devices, ligament and tendon grafts, ocular cell implants, spinal fusion devices, imaging devices, skin substitutes, dural substitutes, bone graft substitutes, wound dressings, and hemostats.

Lower molecular weight polymers and copolymers of P4HB and  
20 copolymers thereof can also be used to modulate endogenous levels of 4-hydroxybutyrate as disclosed by US Patent No. 6,623,730 to Williams and Martin.

Lower molecular weight polymers and copolymers of P4HB and copolymers thereof can also be used in implantable applications that require  
25 a more rapid rate of degradation or absorption than the higher Mw polymers. Preferably, the implanted device will degrade and the low Mw polymer will be absorbed within six months

P4HB polymers and copolymers with low molecular weights may also be used in blends with other materials to improve polymer properties.  
30 The low molecular polymers may also be used in the synthesis of other materials, for example, in reactive polymerization.

## II. Methods of Manufacturing Low Molecular Weight P4HB and Copolymers.

### A. Method of Making Low Molecular Weight P4HB Polymer

In a preferred method, a low molecular weight ( $M_w$ ) P4HB polymer  
5 or copolymer may be prepared as follows. Pellets of a P4HB polymer are  
suspended in aqueous acetic acid, and placed in a shaker incubator. A  
number of parameters can be varied to control the hydrolysis of the polymer  
or copolymer including, but not limited to, the concentration of the acid, the  
type of acid, the temperature of the reaction, the speed (rpm) of the shaker  
10 (or stirrer speed), and the reaction time.

When the desired molecular weight ( $M_w$ ) is achieved, the reaction is  
quenched by decanting the acid, and rinsing the polymer or copolymer with  
water. Residual acid and water may be removed by drying *in vacuo*.

The present invention will be further understood by reference to the  
15 following non-limiting examples.

#### Example 1: Hydrolysis of P4HB with 12M Aqueous Acetic Acid

##### Materials and Methods

30 grams of P4HB pellets (Tepha, Inc., Lexington, MA) ( $M_w$  367  
kDa) were suspended in 100 mL of 12 M aqueous acetic acid (AcOH), and  
20 incubated at 37°C at 50 rpm in a shaker incubator. After 4 and 27.5 hours,  
the  $M_w$  of polymer samples taken from the reaction were 115 and 40 kDa,  
respectively.

##### Results

After 4 hours the P4HB pellets became sticky and the AcOH solution  
25 turned cloudy. After 30 hours, the whole reaction mixture appeared milky,  
and when cooled down, it gelled into a semi-solid. It was therefore  
determined that 12 M AcOH is too strong to be used as the hydrolysis  
medium for P4HB pellets since this concentration may partially dissolve the  
polymer. As a result, the collection of the hydrolysis products would less  
30 practical and the reaction conditions would be less homogeneous with some

hydrolysis occurring in solution and some in the solid phase (i.e. within the pellets).

**Example 2: Hydrolysis of P4HB with 10 M Aqueous Acetic Acid**

Materials and Methods

5           30 grams of P4HB pellets (Tepha, Inc., Lexington, MA) ( $M_w$  367 kDa) were suspended in 100 mL of 10 M aqueous acetic acid, and incubated at 37°C at 50 rpm in a shaker incubator. A sample was removed after 4 hours, and the weight average molecular weight of the polymer was determined by GPC (relative to polystyrene) to be 224 kDa. After 27.5  
10       hours, the reaction was quenched by decanting the acetic acid, and rinsing the polymer with distilled water.

Results

          The pellets did not clump or aggregate during the reaction time, as was seen for the similar reaction performed in 12 M acetic acid. The  
15       polymer pellets were then dried *in vacuo* to remove residual acetic acid and water.

          The weight average molecular weight of the polymer was determined to be 85 kDa after 27.5 hours, and the polymer was recovered in high yield and without loss of material.

20       **Example 3: Hydrolysis of P4HB with 8M Aqueous Acetic Acid**

Materials and Methods

          A 20 gram sample of P4HB pellets (Tepha, Inc., Lexington, MA) ( $M_w$  347 kDa) was suspended in 200 mL of 8 M aqueous acetic acid, and shaken at 50 rpm at 37°C in a shaker incubator. Samples were removed  
25       periodically, and the weight average molecular weight of the polymer and polydispersity were determined by GPC (relative to polystyrene).

Results

          The results are tabulated below (time in hours).

TABLE 1: Molecular Weight and PDI of P4HB over Time

5		8M, 40°C, oil bath, Pellets	
		M <sub>w</sub> (kDa)	PDI
	0	347	2.13
	1	335	2.15
	2	315	2.10
10	4	284	2.17
	6	263	2.08
	8	255	2.05
	24	161	1.97
	96	68	1.90
	120	60	1.94

**Example 4: Hydrolysis of P4HB with 5M Aqueous Acetic Acid**Materials and Methods

15 A 20 gram sample of P4HB granules (Tepha, Inc., Lexington, MA) (M<sub>w</sub> 347 kDa) was suspended in 200 mL of 5M aqueous acetic acid, and stirred at 45°C. Samples were removed periodically, and the weight average molecular weight of the polymer was determined by GPC (relative to polystyrene).

20 Results

The results (average of three runs) are tabulated in Table 2.

TABLE 2: Molecular Weight and PDI of P4HB over Time

	5M, 45°C, Granules	
Time (hours)	Mw (kDa)	PD
0	347	2.13
4	280	2.12
22	168	2.03
29	137	1.98
96	60	2.01

**Example 5: H-NMR Analysis of P4HB Acetic Acid Hydrolysis Product**

The  $^1\text{H}$  NMR spectrum of the hydrolysis product from Example 2 after 27.5 hours is shown in Figure 2. As expected, this low Mw hydrolysis product shows a small  $^1\text{H}$  peak of the polymer end group  $-\text{CH}_2\text{OH}$  at a chemical shift of about 3.69 ppm. The integration area of this peak is 0.50 compared to an integration area of about 100 for the polymer methylene group at chemical shift of about 4.12 ppm. As such, the end group ratio of this sample is 0.5/100, or 0.005, which would suggest the product is a 200 mer (i.e. approx. Mn 17 kDa). This value of Mn from end group analysis is reasonable considering the polymer's GPC  $M_w$  of 85 kDa and  $M_n$  of 44 kDa. (Note: The GPC values relative to PS are about double the absolute values for the polymer from LLS).

The hydrolysis of P4HB pellets or granules suspended in aqueous solution of acetic acid has been performed successfully under mild conditions with reasonable reaction times. The hydrolysis product, low Mw P4HB, was prepared in a high yield, close to 100%, and its Mw could also be predicted based on the Mw versus reaction time curve under fixed reaction conditions, i.e., temperature and concentration of AcOH. Surprisingly for a biphasic reaction, the polydispersity of the hydrolysis products are low and similar to that of the starting polymer, about 2, showing that the hydrolysis reaction occurs uniformly throughout the bulk of the material, rather than being localized to the surface, even though the pellets/granules remain undissolved and suspended in the acetic acid solution.

From the NMR analysis, it appears that the end groups are hydroxyl groups just like the starting polymer. This shows that no new functional groups (i.e. acetate groups) have been added to the polymer and confirms the reaction as a true hydrolysis with no derivatization of the terminal end groups.

The kinetics of the hydrolysis reaction could be affected by a couple of factors such as the reaction temperature (room temperature to 50 °C) and the concentration of AcOH solution (5 ~ 10 M). Because the P4HB

pellets/granules were simply suspended in the AcOH solution at relative low temperatures instead of forming a homogeneous solution and the ratio of P4HB/AcOH could be 3g/10mL, the hydrolysis reaction described herein should be scalable for production of P4HB oligomer with controlled

5    molecular weight.

We claim:

1. A poly-4-hydroxybutyrate polymer or copolymer thereof, wherein the polymer or copolymer is derived by acidic hydrolysis of a higher molecular weight poly-4-hydroxybutyrate polymer or copolymer, and wherein the polymer or copolymer has a weight average molecular weight between 1,000 and 250,000 Da.

2. The polymer or copolymer of claim 1 wherein the polymer or copolymer is suspended as pellets or particles in an aqueous acidic solution for a period of time and at a temperature to hydrolyse the polymer.

3. The polymer or copolymer of claim 2 wherein the higher molecular weight poly-4-hydroxybutyrate polymer or copolymer are in pellet form during hydrolysis.

4. The polymer or copolymer of claim 1 wherein aqueous acetic acid is used for the acidic hydrolysis of the polymer or copolymer.

5. The polymer or copolymer of claim 1 wherein the polydispersity after acidic hydrolysis is between 3 and 1.

6. A medical device comprising the polymer or copolymer of any of claims 1-5.

7. The device of claim 6 selected from the group consisting of a suture, stent, stent graft, stent coating, drug delivery device, device for temporary wound or tissue support, device for soft or hard tissue repair, repair patch, tissue engineering scaffold, retention membrane, anti-adhesion membrane, tissue separation membrane, hernia repair device, device coating, cardiovascular patch, catheter balloon, vascular closure device, sling, biocompatible coating, rotator cuff repair device, meniscus repair device, adhesion barrier, guided tissue repair/regeneration device, articular cartilage repair device, nerve guide, tendon repair device, intracardiac septal defect repair device, including but not limited to atrial septal defect repair devices and PFO (patent foramen ovale) closure devices, left atrial appendage (LAA) closure device, pericardial patch, bulking and filling agent, plastic surgery devices (including facial and breast cosmetic and reconstructive devices), vein valve, heart valve, bone marrow scaffold, meniscus regeneration device,



ligament and tendon graft, ocular cell implant, spinal fusion device, imaging device, skin substitute, dural substitute, bone graft substitute, wound dressing, and hemostat.

8. The device of claim 6 wherein the device is used for controlled release of a bioactive agent.

9. The device of claim 8 wherein the bioactive agent is a therapeutic, prophylactic, and/or diagnostic agent.

10. The device of claim 9 wherein the bioactive agent is a small-molecule drug, peptide, protein, antibody, sugar, polysaccharide, nucleotide, oligonucleotide, aptamer, siRNA, nucleic acid, and combinations thereof.

11. The device of claim 9 wherein the device is used to raise endogenous levels of 4-hydroxybutyrate in a patient.


12. The polymer or copolymer of claim 1 used as an additive or in a polymer blend.

13. A method of using a device of any of claims 6-11, comprising administering to or implanting in an individual in need thereof a device comprising poly-4-hydroxybutyrate polymers or copolymers with weight average molecular weight below 250,000 Da, wherein the polymers or copolymers are derived by acidic hydrolysis of higher molecular weight poly-4-hydroxybutyrate polymers or copolymers, and wherein the acidic hydrolysis takes place in suspension.

14. A medical device comprising a poly-4-hydroxybutyrate polymer or copolymer, wherein the polymer or copolymer is derived by acidic hydrolysis, and wherein the polymer or copolymer has a weight average molecular weight less than 250,000 Da, and wherein the polymer or copolymer has a polydispersity between 3 and 1.


Pathway enzymes are:

1. Succinic semialdehyde dehydrogenase,
2. 4-hydroxybutyrate dehydrogenase,
3. Diol oxidoreductase,
4. aldehyde dehydrogenase,
5. Coenzyme A transferase and
6. PHA synthetase.



**FIG. 1**

FIG. 2



## INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2012/057277

A. CLASSIFICATION OF SUBJECT MATTER  
INV. C08G63/06 C08G63/08  
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
C08G

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	US 2002/141967 A1 (WILLIAMS SIMON F [US] ET AL) 3 October 2002 (2002-10-03) examples 4,5 table 4 claims 1-10,25,31	1,2,6,7, 11 6-14
X	----- HORI Y ET AL: "Chemical synthesis of high molecular weight poly(3-hydroxybutyrate-co-4-hydroxybutyrate)", POLYMER, ELSEVIER SCIENCE PUBLISHERS B.V, GB, vol. 36, no. 24, 1 November 1995 (1995-11-01), pages 4703-4705, XP004025461, ISSN: 0032-3861, DOI: 10.1016/0032-3861(95)96838-Y table 1 ----- -/-	1-5



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 February 2013

Date of mailing of the international search report

11/03/2013

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040,  
Fax: (+31-70) 340-3016

Authorized officer

Kaul-Buchberger, Eva

## INTERNATIONAL SEARCH REPORT

International application No

PCT/US2012/057277

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MOORE T ET AL: "Chemosynthesis of bioresorbable poly(gamma-butyrolactone) by ring-opening polymerisation: a review", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 26, no. 18, 1 June 2005 (2005-06-01), pages 3771-3782, XP027767944, ISSN: 0142-9612 [retrieved on 2005-06-01] table 6	1-4
X	----- US 2006/177513 A1 (MARTIN DAVID P [US] ET AL) 10 August 2006 (2006-08-10) example 1 claims 1-17	1-4,6-9, 11,13
X	----- US 5 191 016 A (YALPANI MANSSUR [US]) 2 March 1993 (1993-03-02)	1-5
Y	column 5, line 53 - column 6, line 7 column 8, line 32 - column 9, line 8 -----	6-14

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2012/057277

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2002141967	A1	03-10-2002	US 7025980 B1 11-04-2006
			US 2002141967 A1 03-10-2002
			US 2002156128 A1 24-10-2002
-----			
US 2006177513	A1	10-08-2006	AT 481088 T 15-10-2010
			CA 2596283 A1 03-08-2006
			EP 1845951 A2 24-10-2007
			ES 2362221 T3 29-06-2011
			JP 2008528204 A 31-07-2008
			US 2006177513 A1 10-08-2006
			WO 2006081517 A2 03-08-2006
-----			
US 5191016	A	02-03-1993	NONE
-----			